BDTX: Silevertinib delivers best-in-class CNS efficacy in non-classical EGFR-mutated NSCLC, with pivotal trials advancing
Silevertinib shows strong efficacy and CNS activity in non-classical EGFR-mutated NSCLC, with a 60% response rate and 86% CNS response, and is advancing in both NSCLC and GBM. FDA feedback on pivotal trial design is expected in Q4, with trial initiation planned for mid-next year.Based on Black Diam…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.